NantWorks

NantWorks is a privately held American holding company and venture network founded by physician, biotechnology entrepreneur, and investor Patrick Soon-Shiong in 2011. It was established as an umbrella for businesses intended to combine biomedical research, healthcare delivery, data infrastructure, advanced computing, artificial intelligence, communications, and other technology platforms. Rather than operating primarily as a consumer-facing product brand, NantWorks functions as a corporate and innovation house whose subsidiaries, affiliates, investments, and strategic partnerships have pursued projects across life sciences and technology. The company emerged from Soon-Shiong's earlier biotechnology and healthcare ventures. His previous businesses included VivoRx, APP Pharmaceuticals, Abraxis BioScience, and NantHealth. Those companies provided experience in drug development, generic injectable medicines, oncology, health-data infrastructure, and commercialization. NantWorks was conceived as a broader platform linking these areas. Its stated technological interests have included secure networks, cloud-based healthcare information systems, high-performance and supercomputing infrastructure, machine vision, voice and object recognition, low-power semiconductor technology, and forms of augmented or artificial intelligence. Healthcare and biotechnology have remained central to the group. NantWorks has been associated with NantHealth, a healthcare information and data-infrastructure business, and NantOmics, a biotechnology company focused on cancer research and protein-kinase-related drug development. Other companies connected with the network have included NantCell, later associated with ImmunityBio, and NantKwest, an immunotherapy company that became publicly traded before combining with ImmunityBio in 2021. Although those entities have had their own legal structures and shareholders, their development illustrates NantWorks' emphasis on combining biological research, clinical information, computation, and therapeutics. The network has also extended beyond medicine. NantWorks invested in or supported companies involved in digital media, communications, education, commerce, graphene technology, batteries, and renewable materials. Examples reported in connection with the group include investments in Zoom, AccuRadio, Wibbitz, Directa Plus, and Sienza, as well as energy initiatives associated with NantEnergy and NantRenewables. These activities reflect a holding-company model in which NantWorks supplies capital, strategic direction, or technological relationships rather than presenting one standardized product portfolio. The group has developed international partnerships, particularly in South Africa. In 2021, NantWorks participated in the creation of NantSA with the South African government and announced cooperation involving the Council for Scientific and Industrial Research, the South African Medical Research Council, and the Centre for Epidemic Response and Innovation. A manufacturing facility and campus were subsequently opened in Cape Town in 2022, with the stated aim of expanding vaccine and biomanufacturing capabilities in sub-Saharan Africa. NantWorks is closely associated with Patrick Soon-Shiong, who has acted as its founder and principal figure. The broader Nant network has sometimes overlapped with his other holdings and investments, including ImmunityBio and media ownership through NantCapital. Those relationships can make the boundaries between NantWorks, its subsidiaries, and Soon-Shiong's separate investment vehicles difficult to define. NantWorks should therefore be understood as an umbrella venture and holding platform, not as a single operating company with a simple retail product line. Public information about its current subsidiary structure, financial performance, headquarters, and executive roster is limited, so several corporate details remain unconfirmed.

NantWorks was founded in September 2011 by Patrick Soon-Shiong as a corporate network intended to bring together several fields that are usually organized separately. The founding concept linked healthcare and biotechnology with high-performance computing, secure communications, artificial intelligence, machine vision, voice and object recognition, and low-power semiconductor systems. Soon-Shiong's earlier career shaped this model. He had been involved in the creation and sale of pharmaceutical businesses, including APP Pharmaceuticals and Abraxis BioScience, and had also founded NantHealth to develop data infrastructure for healthcare. NantWorks provided an umbrella through which these interests could be expanded into a broader portfolio. The healthcare side of the network included NantHealth, which pursued cloud-based and fiber-optic infrastructure for sharing medical information, and NantOmics, founded in 2013 to investigate cancer medicines based on molecular and protein-kinase research. NantWorks was also associated with NantCell and NantKwest, companies involved in immunotherapy and cancer treatment. NantKwest completed a public offering in 2015, and NantKwest later merged with privately held ImmunityBio in 2021. The resulting public company, ImmunityBio, operates separately as a listed corporation, but the transaction illustrates the relationship between Soon-Shiong's operating companies and the wider Nant ecosystem. NantWorks' investment activity has not been limited to medicine. The group invested in Zoom during its early development and later participated in financing for AccuRadio and Wibbitz. Its broader portfolio and affiliated initiatives have also touched digital entertainment, education, commerce, graphene-based materials, lithium batteries, zinc-air energy storage, and renewable materials. NantEnergy announced work on zinc-air batteries in 2018, while NantRenewables was announced as a biorenewables investment in 2021. These activities support the group's image as a cross-sector technology holding platform rather than a conventional pharmaceutical company. International expansion became more visible through South Africa. In 2021, NantWorks and President Cyril Ramaphosa announced NantSA, a venture intended to improve vaccine-development capacity in sub-Saharan Africa. The collaboration involved South African research and health institutions, including the Council for Scientific and Industrial Research, the South African Medical Research Council, and the Centre for Epidemic Response and Innovation. In 2022, a manufacturing facility and campus opened in Cape Town. The project was presented as part of a larger effort to build regional capacity for vaccine research, production, and response to infectious disease. The corporate boundaries around NantWorks are not always clear in public reporting. Soon-Shiong has used multiple entities, including NantCapital, NantHealth, NantOmics, NantKwest, NantCell, NantEnergy, NantRenewables, and ImmunityBio, and the ownership or operating relationships among them have changed over time. His acquisition of the Los Angeles Times was made through NantCapital rather than NantWorks, although the transaction is relevant to the broader business network surrounding its founder. Similarly, criticism involving the Cynviloq drug transaction concerned NantPharma and Soon-Shiong-related interests rather than establishing a finding against NantWorks itself. NantWorks remains best characterized as a privately held, founder-led holding and innovation network. It has no single flagship consumer product, and public sources do not provide a complete current list of subsidiaries, employees, financial results, or headquarters. Its historical significance lies in its attempt to combine biotechnology, healthcare data, computation, artificial intelligence, communications, and energy technology under one entrepreneurial platform.

1. 2022Cape Town campus opens

   A manufacturing facility and campus associated with NantWorks opens in Cape Town.

   Source
2. 2021NantKwest combines with ImmunityBio

   NantKwest and privately held ImmunityBio combine, creating the publicly traded ImmunityBio, Inc.

   Source
3. 2021NantSA is announced

   NantWorks announces a South African venture and institutional collaborations focused on vaccine development and regional biomanufacturing.

   Source
4. 2018NantEnergy publicizes zinc-air battery work

   NantEnergy announces development of a zinc-air battery system intended to reduce storage costs relative to lithium-ion technology.

   Source
5. 2015NantWorks expands its technology investment portfolio

   The network invests in Wibbitz and remains connected to the public offering of NantKwest, broadening its technology and biotechnology footprint.

   Source
6. 2013NantOmics is established

   NantOmics begins pursuing cancer drug research, including work involving protein-kinase inhibitors.

   Source
7. 2011NantWorks is founded

   Patrick Soon-Shiong establishes NantWorks as an umbrella network for healthcare, biotechnology, computing, communications, and related technology ventures.

   Source

A founder-led technology and life-sciences holding platform positioned around the convergence of healthcare, biotechnology, data, artificial intelligence, advanced computing, secure communications, and energy innovation.

• NantHealth platformsHealthcare information technology2007

  Healthcare data and connectivity infrastructure intended to allow medical information to be shared through cloud-based and secure network systems. NantHealth represents the information-technology side of the Nant ecosystem and was designed to connect clinical data, computational analysis, and healthcare decision-making.

• NantOmics research programsBiotechnology2013

  Cancer research and drug-development activities centered on molecular profiling and protein-kinase-related therapeutic approaches. NantOmics was created as a biotechnology affiliate within the wider Nant network rather than as a consumer-facing brand.

• NantSA vaccine and biomanufacturing initiativeVaccines and biomanufacturing2021

  A South African initiative intended to expand vaccine-development and manufacturing capabilities for the region. It was announced with public-sector and research partners and was followed by the opening of a Cape Town facility and campus.

• NantEnergy zinc-air storage technologyEnergy storage2018

  Energy-storage technology based on zinc-air chemistry. NantEnergy presented the system as a lower-cost alternative for stationary storage, although current commercialization and ownership details are not established in the supplied sources.

• 2021Expand vaccine capacity through NantSAStrategy

  The COVID-19 pandemic highlighted limited vaccine-development and manufacturing capacity in parts of Africa.

  What changed. NantWorks announced NantSA and cooperation with South African research and health institutions.

  Aftermath. A manufacturing facility and campus opened in Cape Town in 2022, although the supplied sources do not document current production volumes or commercial results.

  Source
• 2021Combine NantKwest with ImmunityBioM&A

  NantKwest was a public immunotherapy company and ImmunityBio was a privately held biotechnology company within the broader Soon-Shiong network.

  What changed. The companies merged, with the resulting public company operating as ImmunityBio, Inc.

  Aftermath. ImmunityBio became the listed successor entity and traded on Nasdaq under the ticker IBRX.

  Source
• 2011Create a cross-sector technology and life-sciences holding networkStrategy

  Soon-Shiong's previous pharmaceutical and healthcare-data ventures provided separate capabilities in drug development, clinical information, and infrastructure.

  What changed. NantWorks was formed to coordinate ventures spanning biotechnology, healthcare, artificial intelligence, computing, networking, and energy technology.

  Aftermath. The organization developed into a portfolio of affiliated companies and investments rather than a single operating business with one standardized product line.

  Source

• 2015Cynviloq transaction and alleged failure to advance developmentControversy

  NantPharma acquired Cynviloq from Sorrento Therapeutics. Later allegations claimed that regulatory milestones and patent deadlines were allowed to lapse, effectively preventing the medicine from competing with another product connected to Soon-Shiong's interests. The allegations were reported as a controversy involving related entities; the supplied material does not establish a final adjudication against NantWorks itself.

  Source

• 2022Cape Town manufacturing and research campus opens

  NantWorks and its partners opened a facility and campus in Cape Town intended to support vaccine and biotechnology manufacturing in Africa.

  OtherProduct launch
  Source
• 2021NantSA is announced with South African public-sector partners

  NantWorks announced a South African venture intended to strengthen vaccine development and related capabilities across sub-Saharan Africa, with cooperation from national research and health organizations.

  Other
  Source
• 2021NantWorks announces investment in NantRenewables

  Soon-Shiong announced an investment in NantRenewables at SeaPoint in Savannah, Georgia, extending the group's activity into biorenewable materials.

  Other
  Source
• 2015NantWorks invests in Wibbitz

  The company participated in Wibbitz's Series B financing, adding a digital-content technology investment to its portfolio.

  Other
  Source
• 2014NantWorks invests in AccuRadio

  NantWorks made an investment in digital-radio company AccuRadio, demonstrating the network's interests outside healthcare and biotechnology.

  Other
  Source
• 2013NantOmics is established for cancer drug research

  NantOmics was founded as a biotechnology affiliate focused on cancer treatments and protein-kinase-related drug research.

  Other
  Source
• 2011NantWorks launches as a technology and healthcare venture network

  Patrick Soon-Shiong established NantWorks as an umbrella intended to connect semiconductor technology, supercomputing, secure networks, healthcare, and biotechnology.

  Other
  Source

1. Patrick Soon-Shiong
2. NantWorks official website